Entero Therapeutics, Inc. (ENTO)
Official siteBIOTECHNOLOGY
Last updated: Nov 16, 2026 at 4:00 PM ET
Entero Therapeutics, Inc. (ENTO) Stock Chart
Entero Therapeutics (ENTO) closed at $3.30 on Nov 16, 2026. Its price fell 10.1% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 69.2%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $639,331.61 in Oct 2016 and its lowest $1.02 in Apr 2025, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart ENTO with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for ENTO.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 15.2%, and over 6 months it fell 12.7%. The month-end price fell 71.4% over the 3 years through Oct 2026, a compound annual decline of 34.1%.
| Period | Change |
|---|---|
| 1 month | -21.8% |
| 3 months | -15.2% |
| 6 months | -12.7% |
| 12 months | -10.1% |
| 12 months, with dividends | -10.1% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -71.4% | -34.1% |
| 5 years | -100.0% | -82.7% |
| 10 years | -100.0% | -69.2% |
Price by Year
Its best calendar year was 2025, when the price rose 149.7%, and its weakest was 2022, when it fell 98.0%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $4.96 | +6.4% |
| 2025 | $4.66 | +149.7% |
| 2024 | $1.87 | -85.2% |
| 2023 | $12.60 | -96.6% |
| 2022 | $367.68 | -98.0% |
| 2021 | $18,221.58 | -85.1% |
| 2020 | $122,317.88 | -6.7% |
| 2019 | $131,144.95 | -14.0% |
| 2018 | $152,582.10 | -66.7% |
| 2017 | $458,629.01 | -23.3% |
Trading Range
The price is 22.7% below its 50-day average of $4.27 and 8.4% below its 200-day average of $3.60.
| Measure | Value | Price vs |
|---|---|---|
| Close (Nov 16, 2026) | $3.30 | |
| 50-day average | $4.27 | -22.7% |
| 200-day average | $3.60 | -8.4% |
Price Risk
Over 3 years, its largest fall from a peak was 97.4%.
| Measure | Value |
|---|---|
| 1-year beta | 2.62 |
| Largest fall, 1 year | -61.8% |
| Largest fall, 3 years | -97.4% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About ENTO
What is ENTO's 1-year price change?
Entero Therapeutics's price fell 10.1% over the past 12 months. With dividends included, the 12-month total return was -10.1%.
What is ENTO's 5-year price change?
Entero Therapeutics's month-end price fell 100.0% over the 5 years through Oct 2026, a compound annual decline of 82.7%. These figures leave out dividends.
What is ENTO's beta?
Entero Therapeutics's 1-year beta against the S&P 500 is 2.62, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 61.8%.
Is the ENTO chart free?
Yes. Advanced Charting for ENTO is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
ENTO pages: Overview, Charting, Financials